心力衰竭与终末期肾病血液透析患者动静脉通路通畅性的关联
单中心回顾性分析412例2015至2021年创建血液透析通路的终末期肾病患者,204例(50%)存在既往充血性心力衰竭。心力衰竭组与非心力衰竭组在主要通畅率、主要辅助通畅率和次要通畅率上无显著差异;射血分数<50%者仅次要通畅率显著低于射血分数正常者(1年86% vs 93%,P=0.029);心力衰竭亚组中移植物动静脉通路的主要辅助通畅率(1年39% vs 87%)和次要通畅率(62% vs 95%)显著低于自体动静脉瘘(P均<0.0001)。
要点
- 既往充血性心力衰竭整体未显著影响血液透析通路的长期通畅率。
- 射血分数<50%的患者1年次要通畅率显著低于射血分数正常者(86% vs 93%,P=0.029)。
- 心力衰竭患者中移植物动静脉通路的通畅率显著低于自体动静脉瘘。
核心结论
- 射血分数降低与较低的次要通畅率相关。
- 术前充血性心力衰竭(包括射血分数降低和射血分数保留的心力衰竭)与总体血液透析通路通畅率随时间的变化无显著差异相关。
- 接受移植物动静脉通路的心力衰竭患者通畅率明显差于接受自体动静脉瘘者。
- 对于终末期肾病合并心力衰竭患者,须仔细权衡风险与获益,尤其是射血分数低或无合适静脉行瘘管创建者。
研究设计与样本
- 单中心回顾性审查2015至2021年412例接受血液透析通路创建的终末期肾病患者。
- 根据有无术前充血性心力衰竭分层,充血性心力衰竭定义为临床症状加术前超声心动图证据(左心室射血分数<50%或舒张功能障碍)。
- 采用Kaplan-Meier时间-事件分析评估主要通畅率、主要辅助通畅率和次要通畅率,通畅定义采用文献标准。
- 比较充血性心力衰竭组与非充血性心力衰竭组、射血分数降低与正常者、以及充血性心力衰竭患者中移植物动静脉通路与自体动静脉瘘的通畅率差异。
主要发现
- 纳入204例(50%)经超声心动图确认的术前充血性心力衰竭患者。
- 充血性心力衰竭组男性比例更高,合并糖尿病、慢性阻塞性肺疾病、高血压和脑血管意外史者更多。
- 两组在既往瘘管史(P=0.99)、体重指数(P=0.74)或创建的血液透析通路类型(P=0.54)上无显著差异。
- 充血性心力衰竭组与非充血性心力衰竭组的主要通畅率、主要辅助通畅率和次要通畅率随时间变化均无统计学显著差异(三项log-rank P均>0.05)。
- 射血分数<50%者1年主要通畅率38% vs 射血分数正常者51%,1年主要辅助通畅率76% vs 82%,1年次要通畅率86% vs 93%,仅次要通畅率差异达显著(log-rank P=0.029)。
关键数值与推荐
- 充血性心力衰竭定义:临床症状加术前超声心动图证据(左心室射血分数<50%或舒张功能障碍)。
- 射血分数<50%者1年次要通畅率86% vs 射血分数正常者93%(log-rank P=0.029)。
- 充血性心力衰竭患者中移植物动静脉通路1年主要辅助通畅率39% vs 自体动静脉瘘87%(P<0.0001)。
- 充血性心力衰竭患者中移植物动静脉通路次要通畅率62% vs 自体动静脉瘘95%(P<0.0001)。
临床怎么用
- 对于终末期肾病合并充血性心力衰竭患者,须仔细权衡风险与获益,尤其是射血分数低或无合适静脉行瘘管创建者。
- 原文未据此给出其他推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart disease and chronic kidney disease are often comorbid conditions owing to shared risk factors, including diabetes and hypertension. However, the effect of congestive heart failure (CHF) on arteriovenous fistula (AVF) and AV graft (AVG) patency rates is poorly understood. We hypothesize preexisting HF may diminish blood flow to the developing AVF and worsen patency. METHODS: We conducted a single-institution retrospective review of 412 patients with end-stage renal disease who underwent hemodialysis access creation from 2015 to 2021. Patients were stratified based on presence of preexisting CHF, defined as clinical symptoms plus evidence of reduced left ventricular ejection fraction (EF) (<50%) or diastolic dysfunction on preoperative echocardiography. Baseline demographics, preoperative measures of cardiac function, and dialysis access-related surgical history were collected. Kaplan-Meier time-to-event analyses were performed for primary patency, primary-assisted patency, and secondary patency using standard definitions for patency from the literature. We assessed differences in patency for patients with CHF vs patients without CHF, patients with a reduced vs a normal EF, and AVG vs AVF in patients with CHF. RESULTS: We included 204 patients (50%) with preexisting CHF with confirmatory echocardiography. Patients with CHF were more likely to be male and have comorbidities including, diabetes, chronic obstructive pulmonary disease, hypertension, and a history of cerebrovascular accident. The groups were not significantly different in terms of prior fistula history (P = .99), body mass index (P = .74), or type of hemodialysis access created (P = .54). There was no statistically significant difference in primary patency, primary-assisted patency, or secondary patency over time in the CHF vs non-CHF group (log-rank P > .05 for all three patency measures). When stratified by preoperative left ventricular EF, patients with an EF of <50% had lower primary (38% vs 51% at 1 year), primary-assisted (76% vs 82% at 1 year), and secondary patency (86% vs 93% at 1 year) rates than those with a normal EF. Difference reached significance for secondary patency only (log-rank P = .029). AVG patency was compared against AVF patency within the CHF subgroup, with significantly lower primary-assisted (39% vs 87% at 1 year) and secondary (62% vs 95%) patency rates for AVG (P < .0001 for both). CONCLUSIONS: In this 7-year experience of hemodialysis access creation, reduced EF is associated with lower secondary patency. Preoperative CHF (including HF with reduced EF and HF with preserved EF together) is not associated with significant differences in overall hemodialysis access patency rates over time, but patients with CHF who receive AVG have markedly worse patency than those who receive AVF. For patients with end-stage renal disease and CHF, the risks and benefits must be carefully weighed, particularly for those with low EF or lack of a suitable vein for fistula creation.
引用
- Fisher AT, Mulaney-Topkar B, Sheehan BM, et al. Association between heart failure and arteriovenous access patency in patients with end-stage renal disease on hemodialysis. J Vasc Surg. 2023. PMID: 38157996. doi:10.1016/j.jvs.2023.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。